

REMARKS/ARGUMENTS

In response to the restriction to one invention as required under 35 U.S.C. 121, the applicants elect to have invention III examined. This is detailed in the office action as "III. Claims 6-21 drawn to compositions containing glabridin and methods for treating skin conditions with said compositions."

Claim 1 has been amended to accurately describe the method of the invention and clarify that the composition prepared using this method is 4 wt% to 90 wt% glabridin. Claims 2-5 have been canceled to remove confusion on whether the composition is a "solvent-solvent extract" or "supercritical extract", as these distinct species are not the subject of this invention. Claims 6-16 have been amended based on the examiner's comments. Amended Claim 6 provides a complete description of the composition. Distinct species of tyrosinase inhibitors i.e. tetrahydrocurcuminoids, or soy isoflavones for example, are separately listed in amended claims 7-10. Distinct species of antioxidants i.e. natural extracts, isolated compounds are separately listed in amended claims 11-12. Distinct species of sunscreen agents are separately listed in amended claims 13-15. Natural sunscreen boosters are listed in amended claim 16. Claims 20 and 21 have been amended to reflect their dependency on claim 6.

In view of submitting this response within one month of expiration of the shortened statutory period set for reply in your office action, applicants respectfully request consideration for an extension of time under the provisions of 37 CFR 1.136(a), for which a fee of \$55.00 (Small Entity) is enclosed.

Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

SABINSA CORPORATION

By Muhammad Majeed

Dr. Muhammed Majeed
Chief Executive Officer
Tel: (732) 777 1111